Monopar Therapeutics (MNPR) stock forecast and price target
Price $72.00 · data as of November 13, 2026
12-month price target
Average target$130.17
Upside / downside+80.8%
Analysts12
ConsensusStrong buy
Low $119.00Average $130.17High $145.00
Gold marker: average target · white marker: today’s price ($72.00)
Analyst ratings
Strong buy 4Buy 8Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-2.86 | −54.4% | $0 |
| Next fiscal year ends December 31, 2027 | $-2.98 | −4.3% | $27M |
| Next quarter ends December 31, 2026 | $-0.96 | −57.5% | $0 |
| Quarter after ends March 31, 2027 | $-1.31 | −184.2% | $0 |
Consensus of the analysts covering Monopar Therapeutics, updated daily. In the last 30 days 4 estimates were raised and 4 lowered.
Frequently asked questions
What is the Monopar Therapeutics stock price target?
The average 12-month target from 12 analysts is $130.17, 80.8% above the current price of $72.00 Targets range from $119.00 to $145.00.
Is Monopar Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (4 strong buy, 8 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Monopar Therapeutics expected to earn?
Analysts expect EPS of $-2.86 for the fiscal year ending December 31, 2026 and $-2.98 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.